Article
What the FDA proposed
The proposed rule updates drug establishment registration and listing requirements in two main ways.
- Foreign upstream facilities. Some foreign sites that make drugs or active pharmaceutical ingredients only for other foreign facilities, rather than shipping directly to the U.S., would have to register with the FDA and list what they produce. Today those sites can sit outside the agency’s view even when their output ends up in American medicines.
- Distributed manufacturing. Manufacturers using a hub-and-spoke model, with a central quality hub and multiple equivalent production units, could register the network as a single establishment. Units could be added, moved or removed through a simpler update process, though the FDA would need notice before a unit relocates.
FDA leaders framed the change as a way to trace an active ingredient back to its source and to make it easier for newer manufacturing approaches to operate. The agency said the rule should reduce registration costs for distributed manufacturers.
Why hospitals should care
Many shortages that hit hospital pharmacies start far upstream, at an ingredient plant several steps removed from the company whose name is on the label. When regulators cannot see those plants, quality problems surface late, often after supply has already tightened. Better visibility will not end shortages, but it can shorten the time between an upstream problem and a federal response.
The distributed manufacturing provision also matters. Smaller, modular production sites closer to patients are one path to more domestic and resilient supply, especially for older sterile injectables that hospitals depend on. Lowering regulatory friction for those models could help them scale.
What leaders can do now
- Ask suppliers better questions. In contracting, request information on where active ingredients are sourced and whether suppliers have backup sources.
- Use group purchasing leverage. Work with your GPO to favor manufacturers that disclose supply chain detail and maintain redundancy.
- Track high-risk drugs. Keep a short list of critical medicines with a single upstream source and review it with your pharmacy and therapeutics committee each quarter.
- Weigh in. Consider joining your association’s comments so hospital experience with shortages informs the final rule.
Archive entry for Jul 10, 2026, added Nov. 11, 2026.